Moffitt Cancer Center Explore patient stories, our clinical studies, The parties will also enter a long-term supply agreement, which could extend to ten years. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras proposed sale of its ATOM manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the parties ability to consummate such transaction, including the timing thereof, the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the proposed supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the proposed supply agreement and meet Ataras requirements, FDBs potential plans for ATOM, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. Christine Jackman Sclerosis, Clinical In its pursuit to establish itself as a comprehensive healthcare company covering prevention, treatment and diagnosis, FUJIFILM Corporation has made multiple strategic acquisitions over recent years to expand and diversify its healthcare portfolio. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Fujifilm to Acquire Ataras Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million, Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing, Transaction Expected to Result in Reduced Operating Expenses for Atara, Upon Closing, Ataras Cash Expected to Fund Planned Operations into Q4 2023, Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST. FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005459/en/, INVESTORS & MEDIA: "Global Multicancer Screening Market to Reach $7.78 Billion by 2032." Industry Overview. reserved. Through this acquisition by FUJIFILM Corporation, FUJIFILM Diosynth Biotechnologies will solidify its leadership position as a complete solutions-manufacturing provider for advanced therapies. United States of America Morrisville, NC 27560 This acquisition is expected to be completed in April 2022, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The agreement is expected to reduce Ataras planned operating expenses over the multiyear period. 805-395-9669 In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop. We believe that now is the right time for a strategic relationship with FDB to provide us with expert manufacturing capabilities, as needed. We are incredibly proud of our world-class ATOM staff and the facility and believe that this strategic partnership will meet our long-term manufacturing needs. TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. This press release contains or may imply forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Growing our world-class talent and knowledge in manufacturing of advanced therapies is vital to our continued success in supporting our partners in advancing tomorrows medicines, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this. Watertown, MA 02472 For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras proposed sale of its ATOM manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the parties ability to consummate such transaction, including the timing thereof, the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the proposed supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the proposed supply agreement and meet Ataras requirements, FDBs potential plans for ATOM, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. United States of America We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business.. Information for Fujifilm to Acquire Ataras Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million, Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing, Transaction Expected to Result in Reduced Operating Expenses for Atara, Upon Closing, Ataras Cash Expected to Fund Planned Operations into Q4 2023, Company to Host Live Conference Call and Webcast Today at 4pm PST / 7pm EST. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. 805-456-4772 Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of April 4, 2022, 8:01 PM UTC Share this article FUJIFILM Diosynth Biotechnologies has existing locations in Teesside, UK, Research Triangle Park, North Carolina, USA, College Station, Texas, USA and Hillerd, Denmark, the company is currently building new facilities in Watertown, Massachusetts, USA, and Holly Springs, North Carolina, USA. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005459/en/, INVESTORS & MEDIA: With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. Leading Global rewards project planning and execution. TOKYO, April 4, 2022 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. +1 617 798 5211. Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. An archived replay will be available on the Company's website for 30 days. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. 914-789-8523, Photofinishing & Personalized Photo Products. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. (Business Wire) Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of . 914-789-8523, Photofinishing & Personalized Photo Products. Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress, Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty, Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD. 805-395-9669 Strength, Multiple Accordingly, we will further focus capital resources on the development and commercialization of our pipeline of potentially transformative therapeutics for serious diseases.. Atara Receives European Commission Approval for the First Ever Allogeneic T-Cell Immunotherapy. For more information, go to: www.fujifilmdiosynth.com. Media Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Investors HCRx is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. Article Summary FUJIFILM has acquired the facility from Atara Biotherapeutics which is located in Thousand Oaks, California. 2023 Atara Biotherapeutics, Inc. All rights reserved. FDB will also expand use of the Thousand Oaks site and leverage its talented staff to manufacture a broader portfolio of cell therapies. http://www.businesswire.com/news/home/20220401005459/en, 1985 - 2023 BioSpace.com. Powered by Madgex Job Board Software, https://www.businesswire.com/news/home/20220401005459/en/, http://www.businesswire.com/news/home/20220401005459/en. FUJIFILM Diosynth Biotechnologies will retain 134 employees in manufacturing and quality positions at the site. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. After a series of clinical stumbles, Atara lays off 20% of staff and slims R&D focus. This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Press release 2023-04-19, Press release 2022-11-15, Press release 2022-10-27, In Person Lunch & Learn | Process Characterization, Paveway PLUS Microbial Expression Platform, FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO). Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. Eric Hyllengren Investors Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID: 13726583. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Alex Chapman The global multicancer screening market is projected to reach $7.78 billion by 2032 from $1.90 billion in 2022, growing at a CAGR of 15.09% during the forecast period 2023-2032. Information for Improving patients lives is our mission and we will never stop working to bring transformative therapies to those in need. The parties will also enter a long-term supply agreement, which could extend to ten years. 805-395-9669 2023 Atara Biotherapeutics, Inc. All rights Actively contributed and participated in the acquisition of Atara Biotherapeutics. The cell therapy manufacturing facility will advance FUJIFILM Diosynth Biotechnologies global CDMO manufacturing footprint to the West Coast of the United States and complements its existing locations supporting the advanced therapy market in College Station, Texas, U.S.A., Watertown, Massachusetts, U.S.A., and its recently announced BioCampus in the United Kingdom. For more information, please visit: https://www.fujifilmholdings.com. Through this acquisition Fujifilm can extend its CDMO offering to advanced cell therapies. We are incredibly proud of our world-class ATOM staff and the facility and believe that this strategic partnership will meet our long-term manufacturing needs. As part of a long-term manufacturing and services agreement, FUJIFILM Diosynth Biotechnologies will support the production of Ataras promising clinical and commercial-stage allogeneic cell therapies at the site, including tabelecleucel (tab-cel), currently in phase 3 clinical development and under review to support registration in Europe, for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. Investors SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc., (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Alex Chapman December 20, 2022 Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty READ MORE December 19, 2022 Atara Biotherapeutics' Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD READ MORE MORE NEWS Dig deeper. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Despite also reporting a financial loss for the quarter, Atara's shares climbed nearly 24% Tuesday morning to . achapman@atarabio.com, Atara Cookies are important to the proper functioning of a site. Strength, Multiple FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. Eric Hyllengren FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Thousand Oaks, CA 91320 FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies, will operate the new site. Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. FUJIFILM Corporation will continue to expand its bio CDMO business by leveraging its strength of being able to handle a wide variety of biopharmaceutical process development and manufacturing from clinical to commercial scale for drug products, fill & finish, and packaging. 2022-04-04 TOKYO, April 4, 2022 - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases . Our team has developed processes for our products, scaled them up, and built inventory for clinical trials and the commercial launch of tab-cel. As part of the agreement, FUJIFILM Diosynth Biotechnologies and Atara will enter into a long-term manufacturing and services agreement, which could extend to ten years to support the production of Ataras clinical pipeline, which includes tabelecleucel (tab-cel) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD). Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. Access. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB). For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn. FDB will also expand use of the Thousand Oaks site and leverage its talented staff to manufacture a broader portfolio of cell therapies. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. We will now confidently further focus our capital resources on development and commercialization of our pipeline of first-in-kind therapeutics for severe diseases.. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. ehyllengren@atarabio.com With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. The 90,000 sq. Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. Sign up today for your free Reader Account. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business.. +1 919 337 4400, Belasis Avenue "We are thrilled that through this acquisition we will add approximately 140 talented staff from Atara's cell therapy manufacturing facility to the FUJIFILM Diosynth . At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. Going forward, Fujifilm will, by providing a stable supply of high quality biopharmaceuticals, further advance establishing tomorrows medicines that fulfill unmet medical needs., We are thrilled that through this acquisition we will add approximately 140 talented staff from Ataras cell therapy manufacturing facility to the FUJIFILM Diosynth Biotechnologies family. FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies global network, which is a subsidiary of FUJIFILM Corporation, and a world-leading contract development and manufacturing organization (CDMO).

Used Sportsman 267 Masters For Sale, Are Durham Students Oxbridge Rejects?, Stokes Funeral Home Obituaries, Why Did Charlie Cousins Leave Dr Blake Mysteries, Pictures Of Amanda Blake Before She Died, Articles A